| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | EVP, Prod Dev & Med Aff &CMO | Common Stock | 308K | $7.03M | $22.86 | Apr 3, 2023 | Direct |
| Mural Oncology plc | Chief Medical Officer | Stock Option (right to buy) | 136K | $454K | $3.35 | Dec 14, 2023 | Direct |
| Mural Oncology plc | Chief Medical Officer | Ordinary Shares | 67.9K | $226K | $3.33 | Nov 7, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| MURA | Mural Oncology plc | Nov 7, 2024 | 1 | -$16.9K | 4 | Nov 8, 2024 | Chief Medical Officer |
| MURA | Mural Oncology plc | Dec 14, 2023 | 2 | $0 | 4 | Dec 18, 2023 | Chief Medical Officer |
| MURA | Mural Oncology plc | Nov 15, 2023 | 0 | $0 | 3 | Nov 15, 2023 | Chief Medical Officer |
| EXEL | EXELIXIS, INC. | Apr 3, 2023 | 1 | $0 | 4 | Apr 5, 2023 | EVP, Prod Dev & Med Aff &CMO |
| EXEL | EXELIXIS, INC. | Feb 15, 2023 | 1 | -$313K | 4 | Feb 17, 2023 | EVP, Prod Dev & Med Aff &CMO |
| EXEL | EXELIXIS, INC. | Jan 4, 2022 | 2 | -$146K | 4 | Jan 6, 2022 | EVP, Prod Dev & Med Aff &CMO |
| EXEL | EXELIXIS, INC. | Jan 4, 2022 | 0 | $0 | 3 | Jan 6, 2022 | EVP, Prod Dev & Med Aff &CMO |